At NutraVōs, we believe in something simple: evidence matters, especially during pregnancy.
One of the biggest concerns around herbal supplements like ashwagandha has always been the lack of clinical data in pregnant women. Until recently, most safety discussions were based on theory, animal data, or general caution, not human trials.
A newly published clinical study in Frontiers in Global Women’s Health (February 2026) begins to change that conversation
About the Study
The 12-week prospective, randomized, comparative clinical trial evaluated Ashwagandha Root Extract (300 mg twice daily) alongside standard prenatal iron therapy in 70 pregnant women during their second trimester.
Researchers assessed:
-
Hemoglobin and red blood cell (RBC) markers
-
Perceived stress levels
-
Sleep quality
-
Liver, kidney, cardiac, and thyroid safety markers
-
Adverse events
Key Findings
1. Improved Hemoglobin & RBC Quality
Women receiving ashwagandha plus standard care experienced a significantly greater rise in hemoglobin by Week 12 compared to standard care alone (p = 0.0030).
Markers of red blood cell quality (MCHC and RDW) also improved significantly.
Why this matters: anemia affects over one-third of pregnant women globally. Supporting healthy hematological parameters is critical for maternal and fetal well-being.
2. Significant Reduction in Stress
By Week 12, perceived stress scores dropped dramatically in the ashwagandha group (p < 0.001), with a large effect size.
Stress during pregnancy is not just emotional, it can influence sleep, nutrient absorption, and overall maternal health.
3. Better Sleep Quality
Participants taking ashwagandha showed improvements in subjective sleep quality, sleep duration, and overall PSQI global scores across multiple time points.
4. No Adverse Events Reported
Importantly, no adverse events or serious adverse events were reported during the study, and liver, renal, cardiac, and thyroid markers remained stable.
What This Means And What It Doesn’t
This study represents one of the first structured human trials evaluating standardized ashwagandha extract in pregnant women.
However:
-
It was open-label.
-
The sample size was modest.
-
Longer-term and larger trials are still needed.
At NutraVōs, we are not advocating that pregnant women take ashwagandha. Our label clearly advises pregnant or nursing women to consult a healthcare professional before use, in accordance with regulatory guidance.
But we are encouraged.
Encouraged to see high-quality, controlled research emerging.
Encouraged to see safety markers carefully monitored.
Encouraged that science is beginning to fill long-standing evidence gaps.
